TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19684236
Drug: Meal related
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal related insulin group
Study: 19684236
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin group
Study: 17454716
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and nicotine patch
Study: 31937442
Drug: Kinesiotaping in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesiotaping in addition to flurbiprofen 200 mg/day
Study: 31937442
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg/day (Control)
Study: 27623523
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of soft tissue and neural mobilization techniques
Study: 25826649
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) administration prior to exposure therapy
Study: 17426195
Drug: Methylprednisolone infusion
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone infusion (1 mg/kg/d)
Study: 1610632
Drug: i.v. fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fluid 1000 ml
Study: 1610632
Drug: ephedrine 24
Normalized name: ephedrine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 24 mg
Study: 1610632
Drug: methoxamine 4
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methoxamine 4 mg
Study: 6380281
Drug: Methadone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (2.5 or 5 mg) + Ibuprofen (600 mg)
Study: 31101688
Drug: Neo‐adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo‐adjuvant chemotherapy (three cycles of platinum/paclitaxel chemotherapy)
Study: 12565779
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel (Instillagel)
Study: 8739937
Drug: Open reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open reduction and internal fixation using self-reinforced polyglycolide (SR-PGA) screws, poly-l-lactide (SR-PLLA) screw, small (SR-PGA) rods, and Kirschner-wires.
Study: 8739937
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment followed by operation for removal of non-united fragment and reattachment of ligaments and muscles.
Study: 1985173
Drug: 4-Hydroperoxycyclophosphamide (4-HC)
Normalized name: HC yellow no. 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Hydroperoxycyclophosphamide (4-HC) at 20 micrograms/mL
Study: 1985173
Drug: 4-Hydroperoxycyclophosphamide (4-HC)
Normalized name: HC yellow no. 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Hydroperoxycyclophosphamide (4-HC) at 40 micrograms/mL
Study: 1985173
Drug: 4-Hydroperoxycyclophosphamide (4-HC)
Normalized name: HC yellow no. 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Hydroperoxycyclophosphamide (4-HC) at 60 micrograms/mL
Study: 1985173
Drug: 4-Hydroperoxycyclophosphamide (4-HC)
Normalized name: HC yellow no. 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Hydroperoxycyclophosphamide (4-HC) at 80 micrograms/mL
Study: 1985173
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment program
Study: 31915040
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of tetracosactide intravenously over 20 min
Study: 28655802
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages containing simple medical facts or quiz questions
Study: 21287410
Drug: Bisoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol treatment group
Study: 21287410
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment group
Study: 16614584
Drug: Low anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low anesthetic dose
Study: 2216613
Drug: High-dose nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nebulized albuterol (0.30 mg/kg body weight)
Study: 2216613
Drug: Standard-dose nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose nebulized albuterol (0.15 mg/kg body weight)
Study: 369923
Drug: Aldactone 100
Normalized name: Aldactone 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactone 100 mg daily
Study: 369923
Drug: Acebutolol and
Normalized name: acebutolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol and Aldactone 200 mg daily
Study: 369923
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Aldactone and acebutolol
Study: 29061739
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg/day, n=17)
Study: 29061739
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg/day, n=16)
Study: 22357166
Drug: IRO-A (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRO-A (15 mg)
Study: 22357166
Drug: IRO-A with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRO-A with niacin (60 mg)
Study: 22357166
Drug: Roxicodone (IRO)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Roxicodone (IRO) (15 mg)
Study: 15810797
Drug: Iron-fortified milk
Normalized name: iron succinyl milk protein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified milk (15 mg of iron per day per 400 ml)
Study: 15810797
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (60 mg of iron per day)
Study: 8534463
Drug: Morphine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine plus scopolamine 0.25 mg via epidural catheter
Study: 8534463
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone 2.5 to 4 mg via epidural catheter
Study: 2324256
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (daily monitoring from the 6th day of stimulation)
Study: 7351723
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g cinoxacin at bedtime for 6 months
Study: 23381297
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily for 5 days
Study: 14593367
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) infused intravenously for 54.2±22.3 hours
Study: 14593367
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) enoxaparin 1 mg/kg b.i.d. subcutaneously for 76.2±28.3 hours
Study: 11192133
Drug: Clarithromycin extended-release
Normalized name: Clarithromycin Extended-Release Tablets
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin extended-release (two 500-mg tablets once daily for 7 days)
Study: 11192133
Drug: Clarithromycin immediate-release
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin immediate-release (one 500-mg tablet twice daily for 7 days)
Study: 8251280
Drug: saline 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 5 ml (control)
Study: 3927342
Drug: Pentobarbital; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital; specific doses not mentioned
Study: 3927342
Drug: Barbital; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barbital; specific doses not mentioned
Study: 3927342
Drug: Ethanol; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol; specific doses not mentioned
Study: 30531305
Drug: Low-dose Vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Vitamin D3 (1000 IU)
Study: 30531305
Drug: Moderate-dose Vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose Vitamin D3 (3000 IU)
Study: 30246286
Drug: Control (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (increased hypoglycemic dosage/addition of another hypoglycemic agent)
Study: 27364043
Drug: Fludrocortisone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (0.05 mg to 0.2 mg daily)
Study: 22569349
Drug: Milk (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (540 g)
Study: 22569349
Drug: Yogurt (540
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt (540 g)
Study: 20425222
Drug: Acute and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute and long-term treatment decisions based on neuroimaging results
Study: 18622778
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) group treatment for 10 weeks
Study: 10969685
Drug: Control (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (15 minutes of prearrest drug-free bypass)
Study: 8794036
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (target trough levels 200 to 400 micrograms/L; group A; n = 15)
Study: 8794036
Drug: Usual cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual cyclosporine dosage (target levels 400 to 600 micrograms/L; group B; n = 15)
Study: 8794036
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (group A)
Study: 8794036
Drug: Usual cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual cyclosporine dosage (group B)
Study: 1583085
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of tetroxoprim (100 mg) and sulphadiazine (250 mg)
Study: 1583085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly mentioned, assumed to be the other tablet formulation)
Study: 28375708
Drug: 22,600-ppm fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22,600-ppm fluoride varnish, toothbrush, 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized, evidence-based prevention advice
Study: 25966108
Drug: active immunotherapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: active immunotherapy with paternal lymphocytes (Control)
Study: 23689739
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 μg) plus oxytocin infusion (20 IU)
Study: 23689739
Drug: Intravenous carbetocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous carbetocin (100 μg)
Study: 23689739
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol plus oxytocin infusion
Study: 12568631
Drug: Rebamipide 300
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 300 mg/day
Study: 2675812
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cholestyramine and simvastatin
Study: 9204747
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) mRNA levels
Study: 7952683
Drug: Portable biofeedback
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Portable biofeedback devices for treating oral dysphagia
Study: 3300758
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg orally
Study: 20413026
Drug: Beta-blocker switches
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker switches
Study: 18477494
Drug: Combination product
Normalized name: Drug-device combination product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination product (diaphragm and gel)
Study: 18477494
Drug: Single product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single product (gel alone)
Study: 15730346
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg daily)
Study: 15730346
Drug: Pramipexole (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (1.5 mg daily)
Study: 12709522
Drug: Individualised smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised smoking cessation intervention including minimal structured counselling (5‐8 minutes), nicotine patches for three months, and three sessions of counselling (2‐3 minutes) over a three month period.
Study: 11420098
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg, orally)
Study: 8505665
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid as tablets (108 mg/d) with iron
Study: 8505665
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid as tablets (108 mg/d) without iron
Study: 3442946
Drug: 40% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% ethanol administered via nasogastric tube until the 5th postoperative day
Study: 3442946
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no alcohol administration)
Study: 25460174
Drug: Flecainide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide infusion during provocative testing
Study: 25460174
Drug: Flecainide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide infusion
Study: 17110590
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) on days 1 and 8 for six cycles
Study: 17110590
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC = 5 mg min/ml) on day 1 plus gemcitabine (1000 mg/m2) for three cycles followed by docetaxel (40 mg/m2) on days 1 and 8 plus gemcitabine (1250 mg/m2) on days 1 and 8 for three cycles (B)
Study: 17110590
Drug: Oxaliplatin (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin (130 mg/m2) on day 1 plus gemcitabine (1250 mg/m2) on days 1 and 8 for six cycles (C)
Study: 14764132
Drug: Intravesical resiniferatoxin
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical resiniferatoxin treatment
Study: 8113116
Drug: External drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: External drainage followed by radiation treatment (including intraluminal brachytherapy with Ir-192) in Group II (9 patients)
Study: 29125325
Drug: DTC television
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTC television ads for branded prescription drugs
Study: 28559269
Drug: Rifampin at
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin at 10 mg/kg/day
Study: 28559269
Drug: Rifampin at
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin at 15 mg/kg/day
Study: 28559269
Drug: Rifampin at
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin at 20 mg/kg/day
Study: 28559269
Drug: Experimental arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arms (all doses)
Study: 11762555
Drug: Omapatrilat (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (25 mg orally or 10 mg intravenously)
Study: 9236652
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mefenamic acid given one hour before hysteroscopy
Study: 7547097
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg tenidap sodium daily for 22 days
Study: 7547097
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo daily for 22 days
Study: 7547097
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg tenidap sodium
Study: 2141313
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg t.i.d.
Study: 2141313
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg t.i.d.
Study: 2141313
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg t.i.d.
Study: 31758734
Drug: Milkshake with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milkshake with resazurin-based solution PrestoBlue (9% v/v)
Study: 25816296
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 to 100 mg daily added to insulin treatment
Study: 25816296
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of insulin treatment
Study: 22312103
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of preoperative chemotherapy with epirubicin 120 mg/m² and ifosfamide 9 g/m² and granulocyte colony-stimulating factor (arm A)
Study: 22312103
Drug: Five cycles
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five cycles of chemotherapy (three preoperative and two postoperative) (arm B)
Study: 20186064
Drug: Fentanyl HCl
Normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl HCl iontophoretic transdermal system
Study: 18082873
Drug: Oral self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral self-reported nonadherence estimates
Study: 18082873
Drug: Oral self-reported
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral self-reported nonadherence at week 4
Study: 8965300
Drug: Titrated antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated antihypertensive treatment
Study: 25888653
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and therapeutic patient education
Study: 25888653
Drug: Manual therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy, therapeutic patient education, and therapeutic exercise protocol
Study: 25888653
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (manual therapy only)
Study: 11689583
Drug: 6% miltefosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% miltefosine solution
Study: 1303534
Drug: Meperidine (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (2.2 mg/kg)
Study: 1303534
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (morphine and meperidine)
Study: 4058985
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 4.0 mg/d
Study: 4058985
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 0.5 mg/d
Study: 4058985
Drug: All women
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All women (regardless of treatment)
Study: 4058985
Drug: Nutritionally relevant
Normalized name: Levant cottonseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritionally relevant doses of vitamin B6
Study: 30272844
Drug: 10% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbohydrate solution (10% glucose water; 5, 10, and 15 mL/kg) administered 2 hours before anesthesia
Study: 27230269
Drug: Modified NFLs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified NFLs (specifically relocating the percent daily value component)
Study: 22869285
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention (comprehensive dietary modification aimed at lowering insulin levels, including cooking classes and meals at the study center at least twice per week)
Study: 19926964
Drug: TMC278 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 25 mg once daily
Study: 19926964
Drug: TMC278 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 75 mg once daily
Study: 19926964
Drug: TMC278 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 150 mg once daily
Study: 19926964
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg once daily (control)
Study: 19926964
Drug: TMC278 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278 (all doses)
Study: 16444102
Drug: Nonpharmacologic forms
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacologic forms of relaxation therapy (mindfulness-based stress reduction, guided imagery, hypnosis)
Study: 14578137
Drug: Vitamins and
Normalized name: multivitamins and iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins and minerals supplement
Study: 8925327
Drug: Original method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original method of determining rectal compliance using a balloon inflated to 60 ml
Study: 8925327
Drug: Original method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original method of determining anal canal compliance using a ring-shaped balloon inflated to 12 ml
Study: 1513728
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (dicloxacillin, cephalexin, or erythromycin orally for seven days)